Elicio Therapeutics Inc (ELTX) Stock Price, Quote & News

Company Profile

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven ca...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 209 0050

Website: elicio.com

Address:

451 D Street, 5th Floor Suite 501, Boston, United States

Cbra May. 17 at 11:00 PM

$ELTX why?

1 · Reply

laaarsas May. 17 at 8:56 PM

$ELTX This will never work

0 · Reply

nhyujm6 May. 15 at 7:58 PM

$ELTX my estimates suggest a HR of 0.50-0.60, 16-20 mo DFS for treatment arm with a chance DFS not yet met. Transformative for $ELTX - again - the answer is in plain sight, but no one is paying attention, yet at least.

1 · Reply

HboFam May. 15 at 4:07 AM

$ELTX maybe after the next offering afyer phase 2 results will be a nasty haircut cash only to q4

0 · Reply

DiscipleOfZorba May. 15 at 3:58 AM

$ELTX Amplify survival anomaly is even more profound than REGAL and $SLS loading up on $ELTX to secure the mKRAS dynasty You can’t fluke an 18 sigma anomaly

0 · Reply

awesomesaucer1111 May. 15 at 2:36 AM

$ELTX thinking of buying, any near term price targets?

1 · Reply

Woooehoo May. 13 at 12:55 PM

$ELTX what are people’s thoughts on their quarterly update? Generally I’m thinking this should be a 1b market cap on great data (and financing). When you look at fully diluted shares - the true current market cap is ~400m (~30x cash) - I would think is the upper range for a company with one lead program and 14m of cash (no cash to fund a phase 3, barely enough for a going concern) I think the data has to be great to meaningfully move up from here. If the data is neutral-good we go down and sideways. Bad is the same in any scenario. What do people think?

3 · Reply

TheManUpstairs May. 12 at 7:45 PM

Unlike competitors chasing single targets, $ELTX ’s ELI-002 targets 7 different KRAS mutations simultaneously. This multi-valent approach covers 99% of KRAS-driven pancreatic cancers, transforming a niche treatment into a massive blockbuster opportunity ∠( ᐛ 」∠)_

1 · Reply

mktrdr59 May. 12 at 2:51 AM

$ELTX The measured move price projection, the Fib 62% price retracement & this morning's high are all just above $11. Don't know if it will get there, don't know if it will hold there, but it could be a low risk set up to go long.

1 · Reply

Woooehoo May. 11 at 6:36 PM

$ELTX wont take much buying to move this

0 · Reply

Elicio Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

May 11, 2026, 4:05 PM EDT - 6 days ago

Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Apr 30, 2026, 8:00 AM EDT - 17 days ago

Elicio Therapeutics to Present at the Bank of America Healthcare Conference

Apr 16, 2026, 8:00 AM EDT - 4 weeks ago

Elicio Therapeutics Reports Inducement Grants

2026-04-15T11:02:32.000Z - 4 weeks ago

Elicio Therapeutics initiated with a Buy at Ladenburg

2026-03-17T12:15:14.000Z - 2 months ago

Elicio Therapeutics reports inducement grants

2026-03-13T10:15:32.000Z - 2 months ago

Elicio Therapeutics price target raised to $17 from $13 at H.C. Wainwright

Mar 12, 2026, 4:05 PM EDT - 2 months ago

Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

2026-03-09T20:20:28.000Z - 2 months ago

Elicio Therapeutics initiated with a Buy at Rodman & Renshaw

Mar 4, 2026, 1:10 PM EST - 2 months ago

Elicio Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-27T21:31:19.000Z - 2 months ago

Elicio Therapeutics files $400M mixed securities shelf

Feb 25, 2026, 8:00 AM EST - 2 months ago

Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

2026-02-18T13:25:51.000Z - 3 months ago

Elicio Therapeutics reports inducement grants

2026-01-16T13:12:21.000Z - 4 months ago

Elicio Therapeutics reports inducement grants

2025-12-16T13:15:17.000Z - 5 months ago

Elicio Therapeutics reports inducement grants

2025-12-11T13:16:15.000Z - 5 months ago

Elicio Therapeutics’ ELI-002 7P shows antigen spreading in Phase 2 trial

Dec 11, 2025, 8:00 AM EST - 5 months ago

Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial

2025-11-19T13:10:59.000Z - 6 months ago

Elicio Therapeutics appoints Marc Wolfgang as CTO

Nov 19, 2025, 8:00 AM EST - 6 months ago

Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

2025-11-13T22:10:36.000Z - 6 months ago

Elicio Therapeutics files to sell 103,225 shares of common stock for holders

Nov 13, 2025, 4:01 PM EST - 6 months ago

Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

2025-11-07T14:16:06.000Z - 6 months ago

Elicio Therapeutics announces additional data from Phase 2 AMPLIFY-7P trial

Nov 7, 2025, 9:00 AM EST - 6 months ago

Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

Nov 3, 2025, 8:00 AM EST - 6 months ago

Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting

2025-10-27T12:11:08.000Z - 7 months ago

Elicio announces preliminary analysis from Phase 2 AMPLIFY-7P trial

Oct 27, 2025, 8:00 AM EDT - 7 months ago

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

2025-09-29T12:15:50.000Z - 8 months ago

Elicio Therapeutics announces investigator-initiated Phase 1 trial of ELI-002 7P

Sep 29, 2025, 8:00 AM EDT - 8 months ago

Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

2025-09-18T12:10:35.000Z - 8 months ago

Elicio Therapeutics reports inducement grants

2025-09-17T12:05:42.000Z - 8 months ago

Elicio reports ELI-002 7P induced T cell responses in 99% of patients

Sep 17, 2025, 8:00 AM EDT - 8 months ago

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

2025-08-12T12:15:18.000Z - 9 months ago

Elicio announces publication of ELI-002 updated AMPLIFY-201 Phase 1 data

Aug 12, 2025, 8:00 AM EDT - 9 months ago

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

2025-08-05T11:30:30.000Z - 10 months ago

Elicio announces positive recommendation by IDMC to continue ELI-002 Phase 2

Aug 5, 2025, 7:00 AM EDT - 10 months ago

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

2025-07-17T10:11:06.000Z - 10 months ago

Elicio Therapeutics price target raised to $13 from $10 at H.C. Wainwright

Jun 25, 2025, 2:00 PM EDT - 11 months ago

Elicio Therapeutics Transcript: Status Update

2025-06-17T12:21:22.000Z - 11 months ago

Elicio Therapeutics to host virtual KOL event on AMP-powered ELI-002

Jun 17, 2025, 8:00 AM EDT - 11 months ago

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer

Jun 4, 2025, 8:00 AM EDT - 1 year ago

Elicio Therapeutics Secures $10 Million in Financing

May 13, 2025, 4:05 PM EDT - 1 year ago

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Apr 16, 2025, 4:05 PM EDT - 1 year ago

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

Jan 22, 2025, 7:30 AM EST - 1 year ago

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

Dec 12, 2024, 7:00 AM EST - 1 year ago

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Nov 13, 2024, 4:05 PM EST - 1 year ago

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 7, 2024, 4:05 PM EST - 1 year ago

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Sep 13, 2024, 8:30 AM EDT - 1 year ago

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 4:30 PM EDT - 1 year ago

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Jun 27, 2024, 4:05 PM EDT - 2 years ago

Elicio Therapeutics Announces Proposed Public Offering

Jun 27, 2024, 4:01 PM EDT - 2 years ago

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P

May 23, 2024, 5:30 PM EDT - 2 years ago

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

May 15, 2024, 4:30 PM EDT - 2 years ago

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 25, 2024, 8:30 AM EDT - 2 years ago

Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

Apr 5, 2024, 4:30 PM EDT - 2 years ago

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Mar 29, 2024, 8:30 AM EDT - 2 years ago

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

Mar 18, 2024, 8:00 AM EDT - 2 years ago

Elicio Therapeutics Announces $6.0 Million Private Placement Financing

Mar 6, 2024, 8:30 AM EST - 2 years ago

Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

Feb 5, 2024, 8:30 AM EST - 2 years ago

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 25, 2024, 9:00 AM EST - 2 years ago

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Jan 17, 2024, 8:30 AM EST - 2 years ago

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

Jan 16, 2024, 8:30 AM EST - 2 years ago

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

Jan 11, 2024, 8:30 AM EST - 2 years ago

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

Jan 9, 2024, 6:00 AM EST - 2 years ago

Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic's AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002

Dec 22, 2023, 9:00 AM EST - 2 years ago

Elicio Therapeutics Announces $7.0 Million Private Placement Financing

Dec 4, 2023, 8:00 AM EST - 2 years ago

Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 9, 2023, 4:30 PM EST - 2 years ago

Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Nov 3, 2023, 4:30 PM EDT - 2 years ago

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC 2023) Annual Meeting

Cbra May. 17 at 11:00 PM

$ELTX why?

1 · Reply

laaarsas May. 17 at 8:56 PM

$ELTX This will never work

0 · Reply

nhyujm6 May. 15 at 7:58 PM

1 · Reply

HboFam May. 15 at 4:07 AM

$ELTX maybe after the next offering afyer phase 2 results will be a nasty haircut cash only to q4

0 · Reply

DiscipleOfZorba May. 15 at 3:58 AM

$ELTX Amplify survival anomaly is even more profound than REGAL and $SLS loading up on $ELTX to secure the mKRAS dynasty You can’t fluke an 18 sigma anomaly

0 · Reply

awesomesaucer1111 May. 15 at 2:36 AM

$ELTX thinking of buying, any near term price targets?

1 · Reply

Woooehoo May. 13 at 12:55 PM

3 · Reply

TheManUpstairs May. 12 at 7:45 PM

1 · Reply

mktrdr59 May. 12 at 2:51 AM

1 · Reply

Woooehoo May. 11 at 6:36 PM

$ELTX wont take much buying to move this

0 · Reply

justiceforb_85 May. 11 at 4:46 PM

$ELTX wow!

0 · Reply

TheLearningTrader May. 11 at 4:33 PM

$ELTX added today at 12$ Data imminent Presenting on Thursday bodes well

0 · Reply

GA09 May. 11 at 3:19 PM

$ELTX Is there any news or does someone know something?

1 · Reply

TheLearningTrader May. 11 at 3:02 PM

$ELTX 20$ soon

0 · Reply

truehealthvalue May. 7 at 11:34 AM

$ELTX absolutely agree. We are still in the very early days of Elicio full potential. Once they confirm that Eli-007 works the company will unlock all its potential as a platform. I bet some pharmas are already with an eye on us

0 · Reply

nhyujm6 May. 5 at 7:00 PM

$ELTX I bought more over the last few days. Setup is an asymmetric outcome where even modest DFS separation can be clinically meaningful and commercially lucrative. The slower-than-expected event timing combined with ALREADY KNOWN immune response data better than phase I suggests patients are remaining progression-free longer, something the market is underappreciating until the data is released. If the significant DFS plays out as I expect, it validates a platform. The SP is being priced like a binary trial rather than a scalable platform. Big Pharma has repeatedly failed to crack cancer vaccines; a credible signal here would stand out quickly, and acquisition interest becomes a real thing. PS - my calcs has hazard ratio of this trial in the blowout range now. calculations have a

1 · Reply

Cbra May. 5 at 4:30 PM

$ELTX I’d buy more if it does!

0 · Reply

PyroMatic May. 5 at 4:18 AM

$ELTX

0 · Reply

JoshThe3rd May. 5 at 12:46 AM

$ELTX Seems split 50/50 on the bull and bear case. Both sides have valid points. I am leaning bullish but agree with some of the bear points. But even if I was bearish I don't think I could short with this relatively tight range ELTX has been trading in the for the last 3 years. ABVX MDGL went rangebound similarly before they went 500%+ on readouts. Not saying it will 100% happen here again but I haven't found a multi year rangebound biotech that knifed on data. 🤷

1 · Reply

humdime May. 3 at 9:19 AM

$ELTX Not much has been said about AIM therapy based on AMP technology. Injecting a ‘neutral’ vaccine directly into any type of tumor, where it captures tumor antigen information and delivers it to the lymph nodes to generate a systemic immune response. Elegant and practical science. Very strong data—but still in rats. We need to validate the efficacy of ELI-002 7P before we can start viewing the rest of the possibilities within the AMP universe as real assets. Can’t wait for the data.

0 · Reply

Alt_Fuel May. 2 at 1:23 PM

$VSTM $ELTX $ERAS $IMRX $RVMD Verastem Oncology - conference call and webcast to discuss its first quarter 2026 financial results and business updates on Thursday, May 7, 2026, at 4:30 pm ET. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://investor.verastem.com/events. A replay of the webcast will be archived and available following the event.

1 · Reply

truehealthvalue Apr. 30 at 1:05 PM

$ELTX only If you have a very high confidence on results you would be presenting here. We might see Elicio as a multi billion company in a few weeks https://elicio.com/press_releases/elicio-therapeutics-to-present-at-the-bank-of-america-healthcare-conference/

0 · Reply

Market Cap	202.88M
Revenue (ttm)	0.00
Net Income (ttm)	-39.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	5.74

Volume	119,000
Avg Vol	133,394
Day's Range	N/A - N/A
Shares Out	19.09M
Stochastic %K	26%
Beta	1.12
Analysts	Strong Sell
Price Target	$17.33